C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: c4therapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/29/2024 | $6.00 | Underweight → Neutral | JP Morgan |
12/13/2023 | $2.00 → $12.00 | Hold → Buy | Stifel |
2/24/2023 | $12.00 → $10.00 | Underperform → Neutral | Credit Suisse |
2/24/2023 | $15.00 → $5.00 | Neutral → Underweight | JP Morgan |
11/4/2022 | $22.00 → $15.00 | Overweight → Neutral | JP Morgan |
10/11/2022 | $6.00 | Underweight | Morgan Stanley |
4/28/2022 | $10.00 | Underperform | Credit Suisse |
4/11/2022 | $46.00 → $15.00 | Buy → Neutral | BofA Securities |
3/10/2022 | $43.00 | Overweight | JP Morgan |
2/11/2022 | $57.00 | Outperform | BMO Capital Markets |
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative to Approved and Investigational IKZF1/3 Degraders – – On-Target Dose Limiting Toxicity Observed; Modeling Suggests Differentiated Activity and PK Profile Provides Pathway to Increase Therapeutic Index with Alternative Dosing Schedule – – Company to Host Conference Call and Webcast Today at 2 pm ET – WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical co
- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentations – - Conference Call and Webcast Scheduled for April 8, 2022, at 2 PM ET– WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will pr
JP Morgan upgraded C4 Therapeutics from Underweight to Neutral and set a new price target of $6.00
Stifel upgraded C4 Therapeutics from Hold to Buy and set a new price target of $12.00 from $2.00 previously
Credit Suisse upgraded C4 Therapeutics from Underperform to Neutral and set a new price target of $10.00 from $12.00 previously
JP Morgan downgraded C4 Therapeutics from Neutral to Underweight and set a new price target of $5.00 from $15.00 previously
JP Morgan downgraded C4 Therapeutics from Overweight to Neutral and set a new price target of $15.00 from $22.00 previously
Morgan Stanley initiated coverage of C4 Therapeutics with a rating of Underweight and set a new price target of $6.00
Credit Suisse initiated coverage of C4 Therapeutics with a rating of Underperform and set a new price target of $10.00
BofA Securities downgraded C4 Therapeutics from Buy to Neutral and set a new price target of $15.00 from $46.00 previously
JP Morgan initiated coverage of C4 Therapeutics with a rating of Overweight and set a new price target of $43.00
BMO Capital Markets resumed coverage of C4 Therapeutics with a rating of Outperform and set a new price target of $57.00
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. "We are excited to welcome Steve to the Board of Directors and leverage his decades of experience leading discovery strategies for global pharmaceutical companies focused on designing innovative molecules, many of which have successfully mo
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences. Fireside Chat Details: Event: Wells Fargo Healthcare Conference taking place in Boston, MADate/Time: September 5, 2024 at 8:45 AM ET Event: 2024 Cantor Global Healthcare Conference taking place in New York, New YorkDate/Time: September 18, 2024 at 8:35 AM ET Live webcasts will be available on the Investors section of the company's website at www.c4therapeutics.com. Archived replays
WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the ESMO Congress decided to move C4T's previously accepted preliminary monotherapy Phase 1 abstract for CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, to an oral presentation. This oral presentation session at the ESMO Congress 2024 is scheduled for Friday, September 13, 2024, at 4:00 pm to 5:30 pm CEST. Additionally, C4T announced it will host an investor webcast on Friday, September 13, 2024. Updated Details for ESMO Congress 2024 PresentationTitle: Preli
Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer Cemsidomide Phase 1 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress through Dose Escalation; Data on Track for Q4 2024 Cash, Cash Equivalents and Marketable Securities of $295.7 million as of June 30, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein de
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain. Details of the presentation are as follows: Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Muta
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Protein Degradation (TPD) Day taking place virtually on July 15, 2024. Fireside Chat Details:Event: UBS TPD DayDate/Time: Monday, July 15, 2024 from 12:00 pm ET – 12:30 pm ET A live webcast will be available on the Investors section of the company's website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 30 days following the live event. About C4 Therap
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company. Ron Cooper, a global biopharm
USA News Group Commentary VANCOUVER, BC, May 28, 2024 /CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher anal cancer mortality for women. Worldwide, improved access to testing led to a 4.2% increase in HIV diagnoses in the EU and a whopping 120% increase in Montreal, Canada. With sufferers of these types of cancers seemingly getting younger, and at increased danger for those also diagnosed with HIV, biotech companies are working to improve our chances to beat this
USA News Group Commentary VANCOUVER, BC, May 28, 2024 /PRNewswire/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher anal cancer mortality for women. Worldwide, improved access to testing led to a 4.2% increase in HIV diagnoses in the EU and a whopping 120% increase in Montreal, Canada. With sufferers of these types of cancers seemingly getting younger, and at increased danger for those also diagnosed with HIV, biotech companies are working to improve our chances to be
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today repor
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
ARS - C4 Therapeutics, Inc. (0001662579) (Filer)
DEFA14A - C4 Therapeutics, Inc. (0001662579) (Filer)
DEF 14A - C4 Therapeutics, Inc. (0001662579) (Filer)
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company. Ron Cooper, a global biopharmaceutical executive experienced across discovery, development and commercialization, has been appointed chairman of C4T's Board of Directors. Bruce Downey, who served as chairman between June 2022 and June 2024, remains a member of the Board of Directors. As part of C4T's continued Board evolution with this appointment, Glenn Dubin, who has served on C4T's Board of Directors since 20
C4 Therapeutics (NASDAQ:CCCC) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 0 0 Last 30D 1 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for C4 Therapeutics, presenting an average target of $10.75, a high estimate of $14.00, and a low estimate of $8.00. This upward trend is eviden
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target from $7 to $8.
Stifel analyst Bradley Canino maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $13 to $14.
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor (BRAFi)-resistant melanoma models, and an intracranial model of BRAF V600E metastatic melanoma.CFT1946 is an orally bioavailable BiDAC™ degrader that selectively degrades the BRAF V600X mutant protein and prevents RAF dimer-mediated resistance. While currently approved BRA
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California. Details of the posters are as follows:Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasisAbstract Number: 1658Session Date and Tim
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
3 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. "We are excited to welcome Steve to the Board of Directors and leverage his decades of experience leading discovery strategies for global pharmaceutical companies focused on designing innovative molecules, many of which have successfully mo
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company. Ron Cooper, a global biopharm
Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma Activity and Immunomodulatory Effects to Support CFT7455 in Combination with Novel Multiple Myeloma Agents and as a Monotherapy Maintenance Option CFT7455 in Combination with Dexamethasone Results in IMWG Responses at the First Two Dose Levels Studied in Multi-Refractory Multiple Myeloma Patients Dose Escalation Continues for CFT7455 in Combination with Dexamethasone in Relapsed/Refractory Multiple Myeloma, and as a Monotherapy in non-Hodgkin's Lymphomas; Complete Phase 1 Dose Escalation Dat
WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that it will host a webcast on Tuesday, December 12, 2023 at 4:30 PM ET to present new Phase 1 dose escalation data for relapsed refractory multiple myeloma from the ongoing Phase 1/2 clinical trial of CFT7455, a MonoDAC™ degrader of IKZF1/3, for the potential treatment of relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma. To join the webcast, please
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023. She will succeed Lauren White, who will be leaving C4T to pursue a new role with a commercial-stage pharmaceutical company. Ms. Adams joined C4T in November 2020 as senior vice president, investor relations & corporate communications and a member of the company's management team. She has mor
WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Leonard (Len) Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4T's clinical strategy to advance its promising pipeline of degrader therapies.
– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches – – Dr. Donna Grogan Joins as Accomplished Drug Development and Regulatory Strategy Leader With More than 25 Years of Experience in Developing Novel Therapeutics – – Appointments Highlight C4T's Continued Commitment to Evolving Board Composition – WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, tod
– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and Compensation Committee – – Appointment Reflects C4T's Continued Commitment to Corporate Governance to Support Company Growth – WATERTOWN, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Utpal Koppikar, MBA, to its board of directo